Attached files
| file | filename |
|---|---|
| EX-32.2 - CERTIFICATION - Enochian Biosciences Inc | f10q1217ex32-2_dandrit.htm |
| EX-31.2 - CERTIFICATION - Enochian Biosciences Inc | f10q1217ex31-2_dandrit.htm |
| EX-31.1 - CERTIFICATION - Enochian Biosciences Inc | f10q1217ex31-1_dandrit.htm |
| EX-10.5 - FORM OF CONVERTIBLE NOTE AMENDMENT - Enochian Biosciences Inc | f10q1217ex10-5_dandrit.htm |
| EX-10.4 - AMENDMENT TO CFO SERVICE AGREEMENT - Enochian Biosciences Inc | f10q1217ex10-4_dandrit.htm |
| EX-10.2 - RS CONSULTING AGREEMENT - Enochian Biosciences Inc | f10q1217ex10-2_dandrit.htm |
| EX-4.1 - FORM OF GRANT WARRANT - Enochian Biosciences Inc | f10q1217ex4-1_dandrit.htm |
| 10-Q - QUARTERLY REPORT - Enochian Biosciences Inc | f10q1217_dandritbiotech.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of DanDrit Biotech USA, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2017 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.
| Date: February 9, 2018 | By: | /s/ Eric Leire |
| Name: | Eric Leire | |
| Title: | Chief Executive Officer (Principal Executive Officer) |
A signed original of this written statement required by Section 906, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.